<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719339</url>
  </required_header>
  <id_info>
    <org_study_id>17-013841</org_study_id>
    <secondary_id>1R01HD091185-01</secondary_id>
    <nct_id>NCT03719339</nct_id>
  </id_info>
  <brief_title>VIRTUUS Children's Study</brief_title>
  <acronym>VIRTUUS</acronym>
  <official_title>Validating Injury to Renal Transplant Using Urinary Signatures in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the VIRTUUS Children's Study is to adapt identified and validated adult
      noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status
      in pediatric recipients of kidney allografts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advances in immunosuppressive regimens have significantly improved short-term allograft
      survival for kidney transplant recipients. Yet, long-term allograft survival remains static.
      For children with end-stage renal disease (ESRD), improvements in long-term outcomes are
      greatly needed. Children with ESRD require multiple transplants over a lifetime, incurring
      repeated surgical and immunological risks with each newly transplanted organ. Allograft
      injury occurs primarily due to acute cellular rejection (ACR) and/or antibody mediated
      rejection (AMR) and viral infections, such as BK virus associated nephropathy (BKVN). A major
      hindrance to promoting long-term allograft survival is the lack of non-invasive diagnostic
      and prognostic biomarkers to reliably detect early injury in the allograft before clinical
      manifestations arise.

      The incidence of acute rejection (AR) in children in the first year post-transplant is
      10-13%[1]. The current gold standard for diagnosing AR is core needle biopsy; however, biopsy
      is highly invasive, incurs risk of bleeding and graft loss, is subject to sampling error and
      lacks sensitivity and specificity for early injury. Since immune responses are dynamic over
      time, single biopsies do not adequately capture anti-allograft immunity, but repeat biopsies
      are impractical in children who often require sedation and hospitalization for biopsies.
      Other markers, such as serum creatinine, have low sensitivity and specificity for early
      kidney allograft damage.

      The ability to identify sub-clinical kidney allograft injury using minimally invasive,
      robust, biomarkers with high sensitivity and specificity in pediatric recipients would
      represent a major advance in pediatric kidney transplant care. In the Clinical Trials in
      Organ Transplantation (CTOT)-04 study, a NIH-sponsored, multicenter, prospective study of
      adult kidney allograft recipients, members of the VIRTUUS team were able to diagnose and
      predict ACR using urinary cell mRNA and metabolite profiles with high sensitivity and
      specificity[2, 3]. In addition, the investigators validated a urinary cell mRNA signature
      that distinguishes acute rejection (AR) from acute tubular injury (ATI) and ACR from AMR as
      well as a urinary cell mRNA signature diagnostic and prognostic of BKVN[3-5]. The overarching
      objective of this VIRTUUS proposal is to adapt existing validated adult noninvasive
      diagnostic and prognostic biomarkers to characterize allograft status in pediatric recipients
      of kidney allografts. Specifically, the investigators will investigate 1) whether the adult
      urinary cell 3-gene signature is diagnostic and prognostic of ACR in pediatric recipients of
      kidney allografts, 2) whether the combined metabolite and the urinary cell 3-gene signature
      is diagnostic and prognostic of ACR in pediatric recipients of kidney allografts, 3) whether
      levels of BKV VP-1 mRNA in urinary cells are diagnostic of BKVN, and 4) whether urinary cell
      levels of plasminogen activator inhibitor -1 (PAI-1) mRNA and serum creatinine levels predict
      allograft failure.

      Investigators propose to validate early immunologic markers that have shown to be prognostic
      and diagnostic in adult kidney transplant recipients in pediatric kidney transplant
      recipients. Investigator findings will significantly advance the field of pediatric
      transplantation by moving toward proactive, tailored immunosuppressive regimens that minimize
      morbidity and optimize long-term allograft survival.

      The Investigator's primary objective is to hypothesize that: (i) the adult urinary cell
      3-gene signature will be diagnostic and prognostic of ACR in longitudinally collected urine
      samples from children with kidney transplants; and (ii) combined metabolite and mRNA
      biomarkers have greater ability to diagnose ACR than the mRNA or metabolite signature alone
      and (iii) levels of BKV VP-1 mRNA are diagnostic of BK virus nephropathy (BKVN) and (iv)
      urinary cell levels of plasminogen activator inhibitor-1 (PAI-1) mRNA and serum creatinine
      levels predict allograft failure.

      Investigators seek to:

        1. Determine if the adult urinary cell 3-gene signature is diagnostic and prognostic of ACR
           in pediatric kidney allograft recipients,

        2. Evaluate whether a combined metabolite and the 3-gene urinary mRNA signature is
           diagnostic and prognostic of ACR and

        3. Test the hypothesis that BKV-VP-1 mRNA levels in urinary cells are diagnostic of BKVN,
           and to test the hypothesis that a two variable prediction model composed of urinary cell
           level of PAI-1 mRNA and serum creatinine levels, both measured at the time of BKVN
           biopsy diagnosis, predict future graft failure

      Secondary objectives include the following:

        1. Create a repository of DNA samples from urine, saliva, discarded blood and tissue, and
           deceased donor blood and tissue to use for future research studies that will examine
           genome-wide associations with rejection and viral infections in pediatric kidney
           transplant recipients and

        2. Create a biobank of samples of left-over blood and deceased donor blood to later examine
           associations between urine and blood proteomics and metabolomics.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of CD3E mRNA (CD3-epsilon polypeptide)</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of CXCL10 (chemokine C-X-C motif ligand 10)</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 18s rRNA</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <condition>Pediatric Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Nephropathy</condition>
  <condition>BK Virus (Nephropathy)</condition>
  <condition>Antibody-mediated Rejection</condition>
  <condition>Acute Cellular Graft Rejection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, sputum, urine, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 2 to 18 years of age meeting inclusion criteria will be recruited from the
        participating sites' Nephrology outpatient clinics or inpatient settings. All sites may
        choose to enroll Spanish speaking subjects pending the site has necessary resources to
        translate/interpret study related information. Sites choosing to enroll Spanish speaking
        subjects will have a native speaking translator or interpreter available to prevent any
        miscommunication during the consent process.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 2 to 18 years at the time of recruitment

          -  Receiving the first, or additional, incident kidney transplants.

          -  Have an existing/prevalent transplant with a scheduled kidney allograft biopsy.

          -  Parental/guardian permission (informed consent) and, if appropriate, child assent.

        Exclusion Criteria:

        â€¢ Patient's primary medical team feels the subject's participation is not safe.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brendan Keating, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia and Hospital of The University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHOP</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Kidney allograph</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

